Study: Double-blind randomized phase III trial comparing 24 months of adjuvant ensartinib with placebo after complete resection and planned adjuvant chemotherapy in stage IB–IIIB ALK-positive NSCLC.

Key data: N=274. Among patients with stage II–IIIB disease, 24-month DFS was 86.4% with ensartinib versus 53.5% with placebo; HR 0.20. In the overall stage IB–IIIB population, 24-month DFS was 87.3% versus 57.2%; HR 0.20. CNS recurrence or death was reduced; HR 0.22. OS was immature. Grade ≥3 AEs occurred in 35.8% versus 18.2%, most commonly rash.

Why it matters: Provides strong phase III evidence that adjuvant ALK inhibition substantially reduces recurrence after resection, including CNS recurrence.

Clinical context & caveats: The comparator was placebo after stage-appropriate chemotherapy, whereas adjuvant alectinib is already an established standard based on ALINA. ELEVATE supports ensartinib as another effective option but does not establish superiority over alectinib. OS remains immature.

Link

Study: International randomized phase III trial comparing the anti-TIGIT antibody ociperlimab plus tislelizumab with pembrolizumab in untreated locally advanced, unresectable, recurrent, or metastatic NSCLC with PD-L1 expression ≥50%.

Key data: N=662. The trial was terminated after meeting prespecified futility criteria. Median OS was 31.9 months with ociperlimab plus tislelizumab versus 29.4 months with pembrolizumab; HR 0.97, 95% CI 0.76–1.23. Median PFS was 14.3 versus 10.5 months, and ORR was 61.0% versus 48.8%; these analyses were descriptive. TRAEs occurred in 84.3% versus 79.4%.

Why it matters: Adds another phase III result showing that broad TIGIT escalation does not improve survival over established PD-1 monotherapy in PD-L1-high NSCLC.

Clinical context & caveats: Early termination meant that efficacy analyses were descriptive rather than formally tested. Exploratory TIGIT-expression analyses may inform future selection strategies but are not validated for clinical use.

Link

Study: Single-center open-label randomized phase II trial comparing standard concurrent chemoradiotherapy with a simultaneous integrated boost strategy that delivered 60–70 Gy to gross disease over 25 fractions while limiting dose to surrounding target volumes.

Key data: N=168. Median PFS was 21.0 versus 11.0 months; HR 0.48. Median OS was 42.0 versus 26.0 months; HR 0.55. The SIB group had lower risks of brain metastasis and other distant metastases; subdistribution HRs 0.35 and 0.65, respectively. Radiation pneumonitis was lower with SIB, while most other organ-at-risk doses and toxicities were similar.

Why it matters: Suggests that spatially selective dose escalation may improve outcomes without reproducing the toxicity associated with uniform high-dose radiotherapy.

Clinical context & caveats: The magnitude of benefit requires caution. This was a single-center phase II trial conducted between 2015 and 2018, with heterogeneous chemotherapy and no routine consolidation durvalumab. Validation in a contemporary phase III setting is essential.

Link

Study: Post-hoc analysis of the randomized PACIFIC trial evaluating whether proton pump inhibitor or systemic antibiotic exposure within 30 days before treatment was associated with outcomes after chemoradiotherapy.

Key data: N=660; 449 received durvalumab and 211 placebo. Baseline PPI exposure occurred in 40% and antibiotic exposure in 10%. Among durvalumab-treated patients, PPI exposure was associated with shorter PFS, 9.4 versus 17.2 months; HR 1.57, and shorter OS, 33.0 versus 57.9 months; HR 1.66. Antibiotic exposure was associated with shorter PFS, 9.2 versus 15.6 months; HR 1.50, but not significantly shorter OS; HR 1.33, p=0.16. Neither exposure was associated with outcomes in the placebo group. Treatment-by-PPI interactions were significant for PFS and OS.

Why it matters: Raises concern that commonly used microbiome-disrupting medications may attenuate the benefit of consolidation durvalumab.

Clinical context & caveats: Medication exposure was not randomized, and residual confounding by comorbidity or indication remains likely. Necessary PPIs or antibiotics should not be withheld on the basis of this analysis, but unnecessary use should be reconsidered.

Link

Study: Japanese multicenter single-arm phase II trial evaluating first-line pembrolizumab plus the anti-EGFR antibody necitumumab as a chemotherapy-free regimen in advanced NSCLC with PD-L1 TPS ≥50%.

Key data: N=50; median age 72 years. ORR was 76.0%, including 2.0% complete responses, and median PFS was 15.7 months. Median OS was not reached. Rash occurred in 64.0% and hypomagnesemia in 60.0%. Grade 3 interstitial lung disease occurred in 10.0%, and one grade 5 cardiac arrest was reported.

Why it matters: Shows a potentially active chemotherapy-free strategy for PD-L1-high NSCLC, including patients for whom cytotoxic chemotherapy may be undesirable.

Clinical context & caveats: Small single-arm study without a pembrolizumab control group. The response signal is encouraging, but the incidence of interstitial lung disease and other EGFR-related toxicities warrants caution.

Link

Study: Post-hoc surgical analysis of the randomized phase III Neotorch trial comparing perioperative toripalimab plus chemotherapy with chemotherapy alone in resectable stage III NSCLC.

Key data: Among 404 patients, 314 underwent surgery. Surgery cancellation was less frequent with toripalimab, 17.8% versus 26.7%; p=0.03. Tumor downstaging occurred in 80.7% versus 50.7%; p<0.001, and nodal downstaging in 67.5% versus 48.6%; p=0.001. Any-grade surgical complications occurred in 22.3% versus 15.5%, with grade ≥3 complications in 6.6% versus 3.4%. Minimally invasive surgery, R0 resection, and lobectomy were numerically more frequent with toripalimab.

Why it matters: Supports that perioperative immunochemotherapy can improve downstaging and operability without a clear new perioperative safety signal.

Clinical context & caveats: Post-hoc analysis with nominal p values. The study was conducted in China, included only stage III disease, and the surgical population was highly selected and predominantly male.

Link

Study: Multicenter open-label single-arm phase II trial evaluating anlotinib plus penpulimab as second-line therapy in extensive-stage SCLC after platinum-based chemotherapy.

Key data: N=65. Confirmed ORR was 41.5% and DCR 75.4%. Median PFS was 4.4 months and median OS 10.5 months. Twelve-month OS was 46.7%. Grade ≥3 TRAEs occurred in 23.1%. Exploratory analyses associated lower baseline ctDNA maximum somatic allele frequency with improved survival.

Why it matters: Provides a clinically relevant activity signal for combined antiangiogenic and PD-1 therapy in relapsed SCLC.

Clinical context & caveats: Single-arm study conducted in China. Patients had not received prior immunotherapy, which substantially limits applicability in the current era of routine first-line chemo-IO.

Link

Adjuvant targeted therapy continues to expand across oncogenic drivers. ELEVATE reinforces ALK inhibition as central after resection and demonstrates substantial CNS protection.

Ensartinib appears effective, but the clinically relevant future comparison is with alectinib rather than placebo.

AdvanTIG-302 adds to a consistent pattern of negative phase III TIGIT trials in biomarker-unselected NSCLC populations.

Selective radiotherapy intensification remains scientifically compelling, but the SIB results need contemporary validation alongside consolidation immunotherapy.

Concomitant medications may influence IO outcomes, but association should not be mistaken for causation. Clinically necessary antibiotics and PPIs remain appropriate.

Perioperative immunotherapy appears to improve tumor and nodal downstaging without clearly compromising surgical delivery.

Treatment options after SCLC progression continue to expand, although modern studies must account for prior first-line immunotherapy.

ELEVATE was placebo-controlled and largely conducted in China. It does not directly compare ensartinib with adjuvant alectinib.

AdvanTIG-302 was terminated for futility, making secondary efficacy comparisons descriptive.

The SIB study was single-center, phase II, conducted before durvalumab, and used several chemotherapy backbones.

The PACIFIC comedication analysis was post hoc and vulnerable to confounding by indication despite treatment-by-exposure interaction findings.

Neotorch surgical outcomes were post hoc, with nominal statistical testing and a population that was 90% male.

The necitumumab and ALTER-L041 studies were single-arm phase II trials and should be considered hypothesis-generating.